Episode 44

On the two-year anniversary of the launch of Biotech Hangout (formerly Biotech Clubhouse), Daphne and Josh are joined by Chris Garabedian and Brad Loncar, two of the Biotech Clubhouse co-founders, and Bruce Booth, Dawn Bell & Michal Preminger all drop in. The group kicks off the episode with outlook on 2023 and an in-depth recap of the J.P. Morgan 2023 Healthcare Conference. Overall themes include the “Monday Mystique” of industry pressure to announce deals at the start of the conference, Brad’s successful video series full of conversations with notable biopharma CEOs, diversity & inclusion, and an emerging globalization theme. Hosts also cover M&A, Day One Biopharmaceuticals’ topline data and news in the bispecific and endocrine spaces. The group then highlights the FDA’s recent decision to eliminate the requirement of animal testing before human clinical trials, and they chat about the uptick in clinical holds. Later, Eric Tokat, Partner at Centerview Partners, drops in to talk about his three $1B+ deals announced at the conference, perspectives on the M&A landscape, the attractiveness of commercial to late-stage deals and the shift beyond oncology to more diverse fields like metabolic, cardiovascular and autoimmune therapies. Community of experts and insiders joining Biotech Hangout (formerly known as Biotech Clubhouse) include Daphne Zohar, Josh Schimmer, Bruce Booth, Tim Opler, Chris Garabedian, Michal Preminger, Dawn Bell, Rob Perez, Otello Stampacchia and more.